share_log

Exicure | DEF 14A: Definitive information statements

Exicure | DEF 14A: Definitive information statements

Exicure | DEF 14A：股东委托书决议
美股SEC公告 ·  06/11 12:17
Moomoo AI 已提取核心信息
Exicure, Inc., a biotechnology company specializing in gene regulatory and immunotherapeutic drugs, announced the scheduling of its combined 2024 and 2023 Annual Meeting of Stockholders to be held virtually on June 28, 2024. The meeting will address the election of Class III and Class I directors, ratification of the company's independent auditor, advisory approval of executive compensation, and the frequency of such compensation reviews. The meeting will also cover any additional business that may arise. The record date for determining stockholder eligibility to vote at the meeting is set for May 15, 2024. Stockholders will be able to attend the meeting online, submit questions, and vote their shares electronically. The company did not hold an Annual Meeting in 2023, making this a combined meeting for both years. Proxy materials, including the Proxy Statement and the 2023 Annual Report, are available online for stockholders.
Exicure, Inc., a biotechnology company specializing in gene regulatory and immunotherapeutic drugs, announced the scheduling of its combined 2024 and 2023 Annual Meeting of Stockholders to be held virtually on June 28, 2024. The meeting will address the election of Class III and Class I directors, ratification of the company's independent auditor, advisory approval of executive compensation, and the frequency of such compensation reviews. The meeting will also cover any additional business that may arise. The record date for determining stockholder eligibility to vote at the meeting is set for May 15, 2024. Stockholders will be able to attend the meeting online, submit questions, and vote their shares electronically. The company did not hold an Annual Meeting in 2023, making this a combined meeting for both years. Proxy materials, including the Proxy Statement and the 2023 Annual Report, are available online for stockholders.
生物技术公司exicure，专注于基因调控和免疫治疗药物，宣布将于2024年6月28日在线上举行2024和2023年度股东大会。会议将涉及选举三级和一级董事，审查公司独立审计师的任命，执行薪酬的咨询批准以及执行此类薪酬评审的频率。会议还将涵盖可能出现的任何其他业务。决定股东有权参加股东大会的记录日期定于2024年5月15日。股东将能够在线参加会议，提交问题，并以电子方式投票表决。公司未曾在2023年举行年度股东大会，因此这是两年的联合会议。股东可以在网上获取代理材料，包括代理声明和2023年年度报告。
生物技术公司exicure，专注于基因调控和免疫治疗药物，宣布将于2024年6月28日在线上举行2024和2023年度股东大会。会议将涉及选举三级和一级董事，审查公司独立审计师的任命，执行薪酬的咨询批准以及执行此类薪酬评审的频率。会议还将涵盖可能出现的任何其他业务。决定股东有权参加股东大会的记录日期定于2024年5月15日。股东将能够在线参加会议，提交问题，并以电子方式投票表决。公司未曾在2023年举行年度股东大会，因此这是两年的联合会议。股东可以在网上获取代理材料，包括代理声明和2023年年度报告。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息